Back to Search

GALT

Galectin Therapeutics Inc.
Data: 2026-08-03
$3.03
Price
2.02%
Change
$7.13
52W High
$2.03
52W Low
Full AI Analysis Buy/Sell Forecast Trendline Why Moving Charts Options

Galectin Therapeutics Inc is a clinical-stage biopharmaceutical company. The company focuses on drug research and development to create new therapies for fibrotic disease, cancer, and selected other diseases. Its galectin-3 inhibitor is belapectin (GR-MD-02), which has been demonstrated in preclinical models to reverse liver fibrosis and cirrhosis.

Quick Stats
Aug 03, 2026

51.7

AI Score

HOLD

0.3

Volume Ratio

Aug 13, 2026

Next Earnings

12

+ve Days (30d)

18

-ve Days (30d)

GALT Stock Summary

Last updated Aug 03, 2026

GALT is currently trading at $3.03, positioned below its 200-day moving average of $3.65, suggesting bearish momentum. The stock has a 52-week range of $2.025 to $7.13.

Technical Analysis: The 50-day moving average stands at $3.43, which is above the current price, indicating bearish near-term pressure. The RSI (Relative Strength Index) reads 38.213, suggesting the stock is neutral with balanced momentum.

Money Flow Indicators: The Chaikin Money Flow (20-day) is -0.188, which is negative, suggesting distribution or selling pressure. Our AI-powered investment score rates GALT at 51.7/100 with a HOLD recommendation.

GALT (Galectin Therapeutics Inc.) Indicators

Last updated Aug 03, 2026

Indicator Value
RSI(14) 38.213
CMF (20) -0.188
ROC (10) -24.25
ADX (14) 23.607
Indicator Value
MACD (12,26,9) -0.158
AROONOSC (14) -100.0
WILLAMS %R (14) -94.791
MFI (14) 11.233
GALT Technical Chart
  • Candlesticks: Green = price up, Red = price down. Body shows open/close, wicks show high/low.
  • SMAs: Moving averages help identify trends. Price above SMA = bullish, below = bearish.
  • Options OI: Shows max open interest strikes. High OI = significant price levels.
  • Volume Profile: Shows price levels with most trading activity. POC = Point of Control (highest volume).
  • Earnings: Vertical lines mark earnings dates. Watch for volatility around these dates.
  • Gamma Walls: Key support/resistance from options gamma exposure. Orange = resistance above, Purple = support below.
  • Fibonacci Retracement: Auto-calculated support/resistance levels based on recent high/low. Key levels: 23.6%, 38.2%, 50%, 61.8%, 78.6%.
  • Unusual Activity: Highlights days with abnormal volume (2x+ average) or large price moves (5%+). Red marker = unusual activity detected.
Technical Indicators

Select indicators above to analyze technical patterns

Indicators will appear below the price chart with perfectly aligned dates

Volume Profile Analysis

Horizontal histogram showing volume distribution at each price level with buying/selling pressure

GALT Price vs Max Options Open Interest
GALT Max Change In Options Open Interest

GALT Options - Sort by Max open Interest (near term)

4th August 2026 (Data is delayed in normal mkt. hours)

Type Expiration Strike OI Change in
OI		 Volume Ask PC Delta Vega Volatility % change Track

GALT Daily Out of Money Options - Sort by Max open Interest (near term)

4th August 2026 (Data is delayed in normal mkt. hours)

Type Expiration Strike OI Change in
OI		 Volume Ask PC Delta Vega Volatility % change Track

GALT Daily In the Money Options - Sort by Max open Interest (near term)

4th August 2026 (Data is delayed in normal mkt. hours)

Type Expiration Strike OI Change in
OI		 Volume Ask PC Delta Vega Volatility % change Track

GALT Most Active Options by Volume(near term)

4th August 2026 (Data is delayed in normal mkt. hours)

Type Expiration Strike Volume OI Change in
OI		 Ask PC Delta Vega Volatility % change Track

Galectin Therapeutics Inc. is below both the 50 Day and 200 Day SMA which is considered Bearish.

GALT Moving Averages Analysis

GALT (Galectin Therapeutics Inc.) Simple Moving Averages

Moving Averages are last updated Aug 03, 2026

Days MA
10 3.38
20 3.92
30 4.02
50 3.43
100 2.96
200 3.65

GALT Fundamental Analysis

P/E (Forward) 4.5434
P/E (Trailing) --
Market Cap ($) 195.6 million
Earnings/Share ($) -0.41
Net Profit Margin (%) --
Dividend/Share ($) --
EPS Estimate Current Year ($) -0.37
EPS Estimate Next Year ($) -0.33
WallStreet Target Price ($) 11.00
Most Recent Quarter